Idvynso (Doravirine / Islatravir)

Idvynso is a medicine used to treat HIV in adults whose virus is already well controlled. It is a pill that combines two HIV medicines, doravirine and islatravir. It works by stopping the virus from copying itself, which keeps the amount of virus in the body low.

Brand names:Idvynso
Medication

What people taking Idvynso (Doravirine / Islatravir) report

Every report comes from a Lived member, sent anonymously.

Have you tried Idvynso (Doravirine / Islatravir) for HIV Infection?

NameHow it went

About Idvynso (Doravirine / Islatravir)

What It's For

Idvynso is a once-daily pill for HIV that combines two antiviral medicines, doravirine and islatravir. It was approved by the FDA in 2026 as a complete treatment on its own, so it is not taken alongside other HIV medicines. It is a switch option, not a first treatment. Idvynso is approved for adults whose HIV is already controlled on another regimen, meaning a viral load (the amount of virus measured in the blood) below 50 copies per milliliter, often called undetectable. They also need to have never had a regimen stop working and to have no known resistance to doravirine. For people who meet those conditions, it offers a way to replace a current regimen with a single tablet that contains two drugs rather than the three found in many common HIV pills.

How It Works

HIV has to copy its genetic material into DNA before it can take over a cell and make new virus. It uses an enzyme called reverse transcriptase to do this, and both medicines in Idvynso block that enzyme in different ways. Doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI). It attaches to the enzyme and changes its shape so it cannot work properly. Islatravir is a nucleoside analog: a look-alike of one of the building blocks of DNA. The body's cells activate it, the virus mistakenly builds it into its new DNA, and the copying process stops. Hitting the same enzyme from two directions keeps the virus from multiplying, which keeps the viral load suppressed and protects the immune system. The medicine controls HIV but does not cure it.

Dosage & Administration

Idvynso is one tablet taken by mouth once a day, with or without food. Each tablet contains 100 mg of doravirine and 0.25 mg of islatravir. Taking it every day at about the same time matters more than with many other medicines, because missed doses let the virus copy itself again and can lead to resistance, which can make this drug and related drugs stop working. If a dose is missed, take it as soon as you remember, unless it is almost time for the next one; do not double up. One combination needs a different schedule. People who also take rifabutin (an antibiotic used for tuberculosis and related infections) take an extra tablet of doravirine alone, sold as Pifeltro, about 12 hours after their Idvynso dose for as long as they are on rifabutin, because rifabutin lowers doravirine levels.

Side Effects

Most people who switched to Idvynso in clinical trials had few side effects, and most of those that occurred were mild or moderate. The most commonly reported were diarrhea, dizziness, tiredness, bloating, and headache, each affecting a few percent of people at most. Less common effects included nausea, stomach pain, gas, unusual dreams, trouble sleeping, and itching or a mild rash. A small number of people had rises in liver enzymes on blood tests, usually without symptoms. Serious skin reactions are rare but have been reported with doravirine-containing treatments. Tell the care team promptly about any new rash. Stop taking Idvynso and get medical care right away if a rash is painful, blisters or peels, comes with sores in the mouth, eyes or genitals, spreads quickly, or comes with fever, swollen glands, or feeling generally very unwell.

Interactions & Warnings

Because Idvynso is a complete HIV regimen, it should not be combined with other HIV medicines. Two in particular, lamivudine and emtricitabine, must not be taken with it because they lower the active form of islatravir in the body. Both are ingredients in many common HIV pills (and emtricitabine is in some HIV prevention pills), so this matters most around the time of a switch. Some medicines speed up the liver's breakdown of doravirine enough that Idvynso may stop controlling the virus. These cannot be used with it: the seizure medicines carbamazepine, oxcarbazepine, phenobarbital and phenytoin; the tuberculosis antibiotics rifampin and rifapentine; enzalutamide (a prostate cancer drug); mitotane (an adrenal cancer drug); and the herbal supplement St. John's wort. Anyone who has recently taken one of these should be off it for at least four weeks before starting. Some chemotherapy medicines also interfere with islatravir, so every prescriber and pharmacist should know you take Idvynso, including for supplements and over-the-counter products. Idvynso does not treat hepatitis B. Many HIV regimens also control hepatitis B, so anyone with hepatitis B who switches needs close monitoring and may need a separate hepatitis B medicine. It is not recommended for people with severely reduced kidney function or on dialysis, or with severe liver disease. Information on use in pregnancy is still limited, so anyone pregnant or planning pregnancy should talk with their HIV clinician about the options.

What to Expect

Because Idvynso is taken by people whose HIV is already controlled, the goal is to keep things the same: an undetectable viral load on a simpler regimen. In two year-long trials, about 1 in 100 people who switched had a detectable viral load at the end, which was as good as staying on their previous treatment, including the widely used three-drug pill Biktarvy. Viral load tests continue after switching to confirm the virus stays suppressed, and the care team will set how often. The few people in the trials whose virus became detectable mostly had past treatment failure or drug resistance, which is why a full treatment history matters before switching. Earlier studies tested islatravir at higher doses, and higher amounts in the blood were linked to lower counts of lymphocytes, including CD4 cells (the immune cells HIV attacks). At the much lower dose in Idvynso, no meaningful drop was seen. Long-term experience outside clinical trials is still limited because the drug is new. Like other HIV treatment, Idvynso is taken indefinitely, and stopping or changing it should be planned with the HIV care team.

Questions to Ask Your Doctor

  1. 1.Does my treatment history, including any past regimen that stopped working or resistance test results, make me a good candidate to switch?
  2. 2.What would I gain by moving to a two-drug pill compared with staying on my current regimen?
  3. 3.Do I have hepatitis B, and if so, how would it be treated and monitored after I switch?
  4. 4.Do any of my current medicines or supplements interact with Idvynso?
  5. 5.When will my viral load be checked after switching, and what happens if it becomes detectable?

Last reviewed • Oct 2026

Educational content, not medical advice.